These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35653195)

  • 41. Loss of Transcription Factor CREBH Accelerates Diet-Induced Atherosclerosis in Ldlr-/- Mice.
    Park JG; Xu X; Cho S; Lee AH
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1772-81. PubMed ID: 27417587
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
    Aalto-Setälä K; Weinstock PH; Bisgaier CL; Wu L; Smith JD; Breslow JL
    J Lipid Res; 1996 Aug; 37(8):1802-11. PubMed ID: 8864964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.
    Karwatowska-Prokopczuk E; Tardif JC; Gaudet D; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Amour ES; Alexander VJ; Xia S; Otvos JD; Witztum JL; Tsimikas S;
    J Clin Lipidol; 2022; 16(5):617-625. PubMed ID: 35902351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
    Dallinga-Thie GM; Berk-Planken II; Bootsma AH; Jansen H;
    Diabetes Care; 2004 Jun; 27(6):1358-64. PubMed ID: 15161788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.
    Yang X; Lee SR; Choi YS; Alexander VJ; Digenio A; Yang Q; Miller YI; Witztum JL; Tsimikas S
    J Lipid Res; 2016 Apr; 57(4):706-13. PubMed ID: 26848137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
    Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
    J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis.
    Koska J; Furtado J; Hu Y; Sinari S; Budoff MJ; Billheimer D; Nedelkov D; McClelland RL; Reaven PD
    J Lipid Res; 2022 Sep; 63(9):100263. PubMed ID: 35952903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
    Wolska A; Lo L; Sviridov DO; Pourmousa M; Pryor M; Ghosh SS; Kakkar R; Davidson M; Wilson S; Pastor RW; Goldberg IJ; Basu D; Drake SK; Cougnoux A; Wu MJ; Neher SB; Freeman LA; Tang J; Amar M; Devalaraja M; Remaley AT
    Sci Transl Med; 2020 Jan; 12(528):. PubMed ID: 31996466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Apoprotein C-III: A review of its clinical implications.
    Jin JL; Guo YL; Li JJ
    Clin Chim Acta; 2016 Sep; 460():50-4. PubMed ID: 27318213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.
    Sundaram M; Zhong S; Bou Khalil M; Links PH; Zhao Y; Iqbal J; Hussain MM; Parks RJ; Wang Y; Yao Z
    J Lipid Res; 2010 Jan; 51(1):150-61. PubMed ID: 19622837
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism.
    Luo M; Peng D
    Lipids Health Dis; 2016 Oct; 15(1):184. PubMed ID: 27770802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Supplementation with carnosine decreases plasma triglycerides and modulates atherosclerotic plaque composition in diabetic apo E(-/-) mice.
    Brown BE; Kim CH; Torpy FR; Bursill CA; McRobb LS; Heather AK; Davies MJ; van Reyk DM
    Atherosclerosis; 2014 Feb; 232(2):403-9. PubMed ID: 24468155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins.
    Tornoci L; Scheraldi CA; Li X; Ide H; Goldberg IJ; Le NA
    J Lipid Res; 1993 Oct; 34(10):1793-803. PubMed ID: 8245727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loss of MLKL (Mixed Lineage Kinase Domain-Like Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis.
    Rasheed A; Robichaud S; Nguyen MA; Geoffrion M; Wyatt H; Cottee ML; Dennison T; Pietrangelo A; Lee R; Lagace TA; Ouimet M; Rayner KJ
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1155-1167. PubMed ID: 32212851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
    Schoenhagen P; Tuzcu EM; Apperson-Hansen C; Wang C; Wolski K; Lin S; Sipahi I; Nicholls SJ; Magyar WA; Loyd A; Churchill T; Crowe T; Nissen SE
    Circulation; 2006 Jun; 113(24):2826-34. PubMed ID: 16769916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted Knockdown of Hepatic SOAT2 With Antisense Oligonucleotides Stabilizes Atherosclerotic Plaque in ApoB100-only LDLr-/- Mice.
    Melchior JT; Olson JD; Kelley KL; Wilson MD; Sawyer JK; Link KM; Rudel LL
    Arterioscler Thromb Vasc Biol; 2015 Sep; 35(9):1920-7. PubMed ID: 26229140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liver-selective γ-secretase inhibition ameliorates diet-induced hepatic steatosis, dyslipidemia and atherosclerosis.
    Kim K; Yu J; Kang JK; Morrow JP; Pajvani UB
    Biochem Biophys Res Commun; 2020 Jul; 527(4):979-984. PubMed ID: 32439159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.